Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $6.2200 (-2.81%) ($6.1200 - $6.5900) on Tue. Aug. 13, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.15% (three month average) | RSI | 56 | Latest Price | $6.2200(-2.81%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 0.5% a day on average for past five trading days. | Weekly Trend | ADMS advances 0.9% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) IGOV(11%) LQD(6%) VCIT(6%) SHY(5%) JETS(4%) | Factors Impacting ADMS price | ADMS will decline at least -1.575% in a week (0% probabilities). INDA(-8%) XLE(-7%) USO(-7%) URA(-7%) BNDX(-7%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -1.575% (StdDev 3.15%) | Hourly BBV | 0 () | Intraday Trend | -3.3% | | | |
|
5 Day Moving Average | $6.16(0.97%) | 10 Day Moving Average | $6.12(1.63%) | 20 Day Moving Average | $6.08(2.3%) | To recent high | -2.8% | To recent low | 23.2% | Market Cap | $176m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |